In a similar study, a rational combination approach aimed at exploring the role of immunogenic oncolytic adenovirus Ad5/3-D24-GM-CSF with pembrolizumab in humanized A2058 melanoma huNOG mouse model showed a significant reduction in tumor volume compared to pembrolizumab treatment alone without lowering body weight [80]. Here, CSF2 is linked to melanoma.